FDA Approves Higher-Dose Semaglutide for Chronic Weight Management

Semaglutide, a GLP-1 receptor agonist, has revolutionized treatment for type 2 diabetes and obesity. While lower doses are established for glycemic control, a significant unmet need persists for more potent, safe, and effective pharmacological interventions for chronic weight management in individuals with overweight or obesity. This approval addresses the critical need for higher-efficacy pharmacotherapy to combat the global obesity epidemic.

The higher-dose semaglutide demonstrated superior efficacy in reducing body weight compared to placebo. Participants treated with semaglutide achieved a mean body weight reduction of 14.9% from baseline, significantly greater than the 2.4% reduction observed in the placebo group (p<0.001). > A remarkable 86.4% of individuals receiving semaglutide achieved at least 5% body weight reduction, compared to only 31.5% in the placebo group (p<0.001). Furthermore, 69.1% of the semaglutide group achieved 10% or more weight loss, and 50.5% achieved 15% or more, compared to 12.0% and 4.9% respectively for placebo (all p<0.001). Significant improvements were also noted in cardiometabolic risk factors, including reductions in systolic blood pressure by 6.0 mmHg and HbA1c by 0.4% in non-diabetic participants. The safety profile was consistent with previous trials, with gastrointestinal events (nausea, diarrhea, vomiting) being the most common adverse events, leading to discontinuation in 4.5% of the semaglutide group versus 2.1% of the placebo group.